ANGPTL3 Human Recombinant Protein
CNY 3,140.00
货期*
2周
规格
Product images
经常一起买 (1)
ANGPTL3 mouse monoclonal antibody, clone OTI5E6 (formerly 5E6)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Species | Human |
Protein Source | Human |
Expression cDNA Clone or AA Sequence |
Ser17-Pro220
|
Tag | C-Fc |
Buffer | Lyophilized from a 0.2 um filtered solution of PBS, 5% Trehalose,pH7.4. |
Note | Recombinant Human Angiopoietin-related Protein 3 is produced by our Mammalian expression system and the target gene encoding Ser17-Pro220 is expressed with a Fc tag at the C-terminus. |
Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
Stability | 12 months from date of despatch |
Reference Data | |
Locus ID | 27329 |
UniProt ID | Q9Y5C1 |
Synonyms | Angiopoietin-related protein 3; ANGPTL3; Angiopoietin-5; ANG-5; Angiopoietin-like protein 3; ANGPT5 |
Summary | Angiopoietin-like 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins. Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. Full length ANGPTL3 circulates in the plasma as do the proteolytically separated N-and C-terminal segments containing the coiled coil domain and fibrinogen-like domains,respectively. ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing circulating triglycerides and HDL phospholipids. ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion or uptake. ANGPTL3 expression in vivo is up-regulated by LXR agonists and down-regulated by insulin, leptin, and agonists of TRβ or PPARβ. |
Protein Families | Druggable Genome, Secreted Protein |
Documents
FAQs |
SDS |
其它ANGPTL3产品
Customer
Reviews
Loading...